References
- Wein W . Drug development: success, problems and pitfalls – the industry perspective . ESMO Open1 , e000033 ( 2016 ).
- DiMasi JA Grabowski HG Hansen RW . Innovation in the pharmaceutical industry: new estimates of R&D costs . J. Health Econ.47 , 20 – 33 ( 2016 ).
- Caldicott DGE Hutchings A Westwell AD . The dark side of pharmaceutical chemistry . Fut. Med. Chem.4 ( 2 ), 129 – 132 ( 2012 ).
- Saleemi S Pennybaker SJ Wooldridge M Johnson MW . Who is ‘Molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves . J. Psychopharmacol.31 ( 8 ), 1056 – 1060 ( 2017 ).
- Parrott AC Downey LA Roberts CA et al. Recreational 3,4-methylenedioxymethamphetamine or ‘ecstasy’: current perspective and future research prospects . J. Psychopharmacol.31 ( 8 ), 959 – 966 ( 2017 ).
- UNODC . Market analysis of synthetic drugs . www.unodc.org/wdr2017/field/Booklet_4_ATSNPS.pdf .
- James E Robertshaw TL Westwell AD Smith AP . Pharmacies as potential providers of harm reduction services: a preliminary online survey . Drug Sci. Policy Law4 , 1 – 14 ( 2018 ).
- Bershad AK Miller MA Baggott MJ Wit H . The effects of MDMA on socio-emotional processing: does MDMA differ from other stimulants?J. Psychopharmacol.30 ( 12 ), 1248 – 1258 ( 2016 ).
- Carhart-Harris RL Nutt DJ . Serotonin and brain function: a tale of two receptors . J. Psychopharmacol.31 ( 9 ), 1091 – 1120 ( 2017 ).
- Wagner MT Mithoefer MC Mithoefer AT et al. Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy . J. Psychopharmacol.31 ( 8 ), 967 – 974 ( 2017 ).
- Passie T . The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985) . Drug Sci. Policy Law4 , 1 – 19 ( 2018 ).
- Mithoefer MC Mithoefer AT Feduccia AA et al. 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomized, double-blind, dose-response, Phase II clinical trial . Lancet: Psychiatry5 , 486 – 497 ( 2018 ).
- Carhart-Harris RL Roseman L Haijen E et al. Psychedelics and the essential importance of context . J. Psychopharmacol.32 ( 7 ), 725 – 731 ( 2018 ).
- Canal CE Murnane KS . The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens . J. Psychopharmacol.31 ( 1 ), 127 – 143 ( 2017 ).
- Bogenschutz MP Forcehimes AA Pommy JA et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study . J. Psychopharmacol.29 ( 3 ), 289 – 299 ( 2015 ).
- Johnson MW Garcia-Romeu A Johnson PS Griffiths RR . An online survey of tobacco smoking cessation associated with naturalistic psychedelic use . J. Psychopharmacol.31 ( 7 ), 841 – 850 ( 2017 ).
- Carhart-Harris RL Bolstridge M Rucker J et al. Psilocybin with psychological support for treatment-resistant depression an open-label feasibility study . Lancet: Psychiatry3 ( 7 ), 619 – 627 ( 2016 ).
- Griffiths RR Johnson MW Carducci MA et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial . J. Psychopharmacol.30 ( 12 ), 1181 – 1197 ( 2016 ).
- Hendricks PS Crawford MS Cropsey KL et al. The relationships of classic psychedelic use with criminal behavior in the United States adult population . J. Psychopharmacol.32 ( 1 ), 37 – 48 ( 2018 ).
- Forstmann M Sagioglou C . Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness . J. Psychopharmacol.31 ( 8 ), 975 – 988 ( 2017 ).
- Lyons T Carhart-Harris RL . Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression . J. Psychopharmacol.32 , 811 – 819 ( 2018 ).
- The National Archives . Psychoactive Substances Act 2016 . www.legislation.gov.uk/ukpga/2016/2/contents .
- WHO . Fact sheet on tobacco . www.who.int/news-room/fact-sheets/detail/tobacco .
- WHO . Fact sheet on alcohol . www.who.int/news-room/fact-sheets/detail/alcohol .